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Summary
Background We designed the EURAMOS-1 trial to investigate whether intensiﬁ ed postoperative chemotherapy for 
patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved 
event-free survival in patients with high-grade osteosarcoma.
Methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients 
with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. 
Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) 
or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratiﬁ cation factors: 
trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of 
metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m², doxorubicin 37·5 mg/m² per 
day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m² over 4 h. The MAPIE 
regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m²) at 2·8 g/m² per day 
with equidose mesna uroprotection, followed by etoposide 100 mg/m² per day over 1 h on days 1–5. The primary 
outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with 
ClinicalTrials.gov, number NCT00134030.
Findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 
618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median 
follow-up was 62·1 months (IQR 46·6–76·6); 62·3 months (IQR 46·9–77·1) for the MAP group and 61·1 months 
(IQR 46·5–75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in 
the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival 
did not diﬀ er between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78–1·23]); hazards were non-proportional 
(p=0·0003). The most common grade 3–4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] 
in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without 
documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 
non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). 
Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was 
normal), which was deﬁ nitely related to their MAP treatment (speciﬁ cally doxorubicin and cisplatin), and one from 
left ventricular systolic dysfunction, which was probably related to MAPIE treatment (speciﬁ cally doxorubicin). 
One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due 
to methotrexate.
Interpretation EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative 
chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with 
increased toxicity without improving event-free survival. The results deﬁ ne standard of care for this population. 
New strategies are required to improve outcomes in this setting.
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Introduction
Treatment strategies for high-grade osteosarcoma with 
multidrug chemotherapy and resection result in 3-year 
event-free survival of 60–70%.1–4 The most common factors 
predicting survival are presence of metastases,1 histological 
response to preoperative chemotherapy,1,5–8 and complete 
surgical resection.1 Three of the active drugs in 
osteosarcoma3 include cisplatin,9–11 doxorubicin,12,13 and 
high-dose methotrexate;14,15 this combination (MAP), given 
preoperatively and postoperatively, is widely used for the 
treatment of osteosarcoma. Ifosfamide with16,17 or without 
etoposide17 also has activity in this setting and when 
incorporated into the treatment of patients with metastatic 
disease seems to improve event-free survival.18 Though 
uncontrolled studies suggested that changing therapy on 
the basis of histological response improves outcomes,3,5,19 
the eﬃ  cacy of this strategy had not been tested in a 
randomised trial.
We report the primary results for patients who had a 
poor response and were randomised to the EURAMOS-1 
trial, a collaboration between the Children’s Oncology 
Group (COG), the Cooperative Osteosarcoma Study 
Group (COSS), the European Osteosarcoma Intergroup 
(EOI), and the Scandinavian Sarcoma Group (SSG). We 
did this trial to assess whether the addition of ifosfamide 
and etoposide to standard postoperative MAP would 
improve event-free survival in patients whose primary 
tumour showed a poor response to preoperative MAP.
Methods
Study design and participants
EURAMOS-1 was an open-label, international, ran-
domised, phase 3, controlled trial. The structure and 
design of this trial have been previously published.20 
After a diagnostic biopsy, patients with newly diagnosed 
osteosarcoma could be registered to this trial. Patients 
were registered from 325 sites in 17 countries. The main 
eligibility criteria for registration included having 
high-grade localised or metastatic extremity or axial 
osteosarcoma deemed resectable by the treating team, 
Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis 
Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, 
Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College 
London Hospitals, and Biomedical Research Centre. 
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Research in context
Evidence before this study
Osteosarcoma is a rare disease but is the most common bone 
tumour in children and adolescents and is associated with high 
mortality. Treatment for osteosarcoma involves multimodality 
therapy with chemotherapy followed by surgical resection and 
further chemotherapy. Before the EURAMOS-1 trial started, 
there has never been a study randomising patients with 
osteosarcoma following surgery to add chemotherapy to the 
preoperative backbone, and a formal literature review was not 
possible. Through collaborations and PubMed searches, we were 
aware of the relevant publications in osteosarcoma which were 
about importance of histological response and use of Ifosfamide 
in treating patients with a poor histological response. 
Histological response, as assessed by examination of the surgical 
specimen, is one of the strongest predictors of longer-term 
outcome for patients with osteosarcoma. Patients who have a 
poor response to chemotherapy (≥10% viable tumour) have a 
substantially worse survival than those with a good response 
(<10% viable tumour) with 5-year overall survival of around 
45–55% and 75–80%, respectively. Several studies suggested 
that altering postoperative therapy might improve the outcome 
for patients with a poor histological response. Only one of the 
studies reporting improved outcome for patients with a poor 
response was randomised. However, the randomised study 
question was a comparison of upfront three-drug therapy versus 
three-drug therapy plus ifosfamide. The postoperative 
treatment for patients with a poor response was 
non-randomised and altered to include ifosfamide. Therefore, 
no previous study has assessed in a randomised comparison 
whether adding an ifosfamide containing combination to 
standard treatment improves the outcome for patients 
identiﬁ ed as having a poor histological response.
Added value of this study
Randomisation of patients with a poor response in EURAMOS-1 
trial represents a large, international comparison, with patients 
registered at the start of treatment and randomly assigned after 
surgery. Preoperative and postoperative chemotherapy was with 
methotrexate, doxorubicin, and cisplatin (MAP), with half of the 
patients also assigned to receive ifosfamide and etoposide. 
Our ﬁ ndings do not support the intensiﬁ cation of postoperative 
chemotherapy by adding ifosfamide and etoposide for patients 
with a poor response to preoperative chemotherapy. 
Implications of all the available evidence
Only a few randomised trials exist of this rare disease. 
The results of this randomised controlled trial will change 
clinical practice and help inform physicians’ decisions when 
managing patients with osteosarcoma whose tumours show a 
poor histological response. Research is needed to improve 
outcomes for all patients with osteosarcoma and future trials 
need access to newer or targeted drugs, driven by improved 
understanding in the biology of the disease.
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age 40 years or younger at diagnostic biopsy; Karnofsky 
or Lansky status of at least 60, normal cardiac function 
(shortening fraction >28%), normal hearing, normal 
bone marrow as shown by an absolute neutrophil count 
of at least 1·5 × 10⁹ cells per L (or a white blood cell count 
of at least 3 × 10⁹ cells per L if neutrophil count is not 
available), and a platelet count of at least 100 000 platelets 
per μL. Patients were also required to have a serum 
bilirubin concentration of at most less than 1·5 times 
the upper limit of normal and a normal creatinine 
concentration for their age as per protocol. Enrolment 
criteria also included no previous treatment for 
osteosarcoma, and if the osteosarcoma was a second 
malignancy, patients could not have received previous 
chemotherapy. Patients’ life expectancy was at least 
3 months. 
The main eligibility criteria for randomisation were 
registeration before deﬁ nitive surgery to take part in 
EURAMOS-1; assessment of histological response in the 
primary tumour and randomisation within 35 days of 
deﬁ nitive surgery (assessment by reference pathologist 
where possible); age 5 years or younger at biopsy for 
patients with good response; provision of all essential 
data (entry form, preoperative chemotherapy forms, 
surgery, and pathology report); receiving exactly 
two courses of cisplatin and doxorubicin, at least 
two courses, and no more than six courses of 
methotrexate; macroscopically complete surgical 
resection of the primary tumour; no evidence of local 
disease progression; recovery from previous therapy 
allowing administration of post operative chemotherapy 
as planned; no progression of metastatic disease or new 
metastases and removal of metastases (in patients with 
metastatic disease at registration) done or deemed 
feasible (to be done after primary surgery); macro-
scopically complete surgical resection of the primary 
tumor; and written consent to participate in the study. 
The data was collected in each data centre (COG, COSS, 
EOI, and SSG) and transferred periodically to the 
coordinating data centre (Medical Research Council 
Clinical Trials Unit). 
   Before enrolment, all institutions were required to have 
obtained all regulatory and ethics approvals in accordance 
to their national, and for European centres, European 
rules and regulations, as mentioned in the protocol. 
All trial participants or legal guardians provided written 
informed consent before beginning protocol therapy. 
The protocol is available online.
Randomisation and masking
Patients were randomly allocated (1:1) to receive either 
MAP or MAP plus ifosfamide and etoposide (MAPIE). 
Treatment allocation was done with centralised imple-
mentation of concealed random permuted blocks 
with three stratiﬁ cation factors: trial group, location of 
tumour (proximal femur or proximal humerus vs other 
limb vs axial skeleton), and presence of metastases 
(no vs yes or possible). Metastases were deﬁ ned as at 
least three lesions bigger than 5 mm or a single lesion 
bigger than 1 cm. Patients with lung lesions not 
meeting these criteria were classiﬁ ed as having possible 
metastases. Patients were randomised centrally through 
Medical Research Council Clinical Trials Unit (COSS, 
EOI, SSG) and COG. The randomisation lists were 
prepared by the Medical Research Council Clinical 
Trials Unit for COSS, EOI, and SSG and by COG for 
COG sites. Each treating institution was responsible for 
enrolling their patients into the trial, and patients were 
assigned to interventions using the Medical Research 
Council Clinical Trials Unit  randomisation system (for 
COSS, EOI, and SSG sites) and the COG randomisation 
system (for COG sites). Patients and investigators were 
not masked to treatment allocation.
Procedures
Baseline assessment required a complete blood count, 
complete set of chemistry test data (including liver 
and kidney function), a baseline echocardiogram and 
hearing test, imaging with an MRI of the primary site, 
and a chest CT scan and a bone scan (a PET scan could 
be used instead). All patients received preoperative 
therapy with MAP20 (appendix p 10) for 10 weeks 
consisting of cisplatin 120 mg/m² (4 h infusion of 
60 mg/m² per day for 2 days in COG sites; continuous 
72 h intravenous infusion in other sites) and 
doxorubicin 37·5 mg/m² per day on days 1 and 2 (on 
weeks 1 and 6). This was followed by high-dose 
methotrexate 12 g/m² over 4 h (maximum dose 20 g at 
COG institutions) with hyper-hydration, alkalinisation, 
and standard leucovorin rescue at a dose of 15 mg/m² 
starting 24–48 h from methotrexate infusion and 
continuing until methotrexate concentration was less 
than 0·1 μM (weeks 4, 5, 9, and 10).20,21 Leucovorin 
rescue was adjusted with the dosing nomogram 
according to the methotrexate concentration. Patients 
were assessed with complete blood counts twice a week 
and with chemical tests (including liver and kidney 
function tests) before every cycle of chemotherapy. 
To begin myelosuppressive cycles, patients needed an 
absolute neutrophil count of at least 750 cells per μL 
and a platelet count of at least 75 000 platelets per μL. 
Criteria for administering high-dose methotrexate were 
diﬀ erent and included an absolute neutrophil count of 
at least 250 cells per μL and a platelet count of at least 
50 000 platelets per μL.
Patients were restaged at 10 weeks preoperatively 
(with the same imaging studies done at diagnosis) and 
investigator-assessed response was reported according 
to Response to Treatment In Solid Tumors (RECIST) 
criteria, version 1. Those patients identiﬁ ed at their local 
institution to have no local or metastatic disease 
progression (deﬁ ned as >20% increase in any primary 
tumour dimension associated with increased pain or 
inﬂ ammation) had primary tumour resection with 
University of Washington, 
Seattle, WA, USA 
(D S Hawkins MD); Abt 
Pädiatrische Radiologie, AKK 
Altonaer Kinderkrankenhaus, 
Hamburg, Germany 
(Prof K Helmke MD); Center for 
Cancer and Blood Disorders, 
Connecticut Children’s Medical 
Center, Hartford, CT, USA 
(M S Isakoff MD); Department 
of Pediatrics, St Anna 
Children’s Hospital, Medical 
University Vienna, Vienna, 
Austria (L Kager MD); University 
Children’s Hospital Basel, Basel, 
Switzerland (Prof T Kühne MD); 
Texas Children’s Cancer Center, 
Baylor College of Medicine, 
Houston, TX, USA (C C Lau MD); 
Department of Pediatrics, UT 
Southwestern and Children’s 
Medical Center, Dallas, TX, USA 
(Prof P J Leavey MD); Center for 
Childhood Cancer and Blood 
Disorders, Nationwide 
Children’s Hospital and 
The Ohio State University, 
Columbus, OH, USA 
(Prof S L Lessnick MD); Division 
of Hematology, Oncology, and 
Blood and Marrow 
Transplantation, Department 
of Pediatrics, Children’s 
Hospital Los Angeles, Keck 
School of Medicine, University 
of Southern California, 
Los Angeles, CA, USA 
(L Mascarenhas MD); 
Department of Pediatrics, 
Memorial Sloan Kettering 
Cancer Center, New York, NY, 
USA (Prof P A Meyers MD); 
University Hospital Motol, 
Pediatric 
Hematology/Oncology, 
Prague, Czech Republic 
(H Mottl MD); Clinical 
Cooperation Group 
Osteosarcoma, Pediatric 
Oncology Center, Department 
of Pediatrics, Technical 
University Munich, Munich, 
Germany (Prof M Nathrath MD); 
Department of Pediatric 
Oncology, Klinikum Kassel, 
Kassel, Germany 
(Prof M Nathrath); National 
Medical Center, Oncology 
Department, Budapest, 
Hungary (Prof Z Papai MD); 
Primary Childrens Hospital, 
The University of Utah, 
Salt Lake City, UT, USA 
(Prof R L Randall MD); HELIOS 
Klinikum Berlin-Buch, Klinik für 
Interdisziplinäre Onkologie, 
Berlin, Germany 
(P Reichardt MD); Department 
of Pediatric Hemato-oncology, 
University Hospital Leuven, 
Articles
www.thelancet.com/oncology   Vol 17   October 2016 1399
centrally reviewed assessment of histological response.22,23 
Because all patients received the same preoperative 
therapy and treatment assignment was decided after 
pathology review, there was no masking. Eligibility for 
postoperative randomisation included macroscopic 
tumour resection, at least 10% morph ologically viable 
tumour, no disease progression, no or resectable 
metastases, and ability to resume therapy within 35 days 
after surgery. We did not include central imaging review 
to conﬁ rm resectability of the disease or radiological 
response. We did not collect the percentage of 
viable tumour for each individual patient but rather 
whether they had at least 10% morphologically viable 
tumour. 
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Figure 1: Trial proﬁ le
*We later found out that one patient actually had a good histological response (allocated to MAP group at randomisation and analysed as in the MAP group). 
†One additional patient completed MAP (as he was not assessed for toxicity, he was excluded previously in this diagram). ‡One patient was lost to follow-up at 
randomisation.
618 patients were randomly assigned*
1060 patients were poor responders
2260 patients were registered
1200 patients were not poor responders
442 excluded
204 did not provide consent
111 had progression (local or distant)
 45 late histology
 31 had incorrect preoperative CT
 16 no removal of  metastasis or unresectable disease
   7 had not recovered from prior therapy
   6 had a change in diagnosis
   5 had incomplete resection of primary tumour
17 other
302 started MAP treatment
301 assessable for toxicity (safety population)
261 completed MAP treatment†
310 assigned to receive MAP (intention-to-treat population) 
8 did not receive MAP
4 treatment refusal
1 protocol violation
1 not in patient’s best interest
2 lost to follow-up
1 not assessed for toxicity
40 terminated treatment early
8 treatment refusal
20 disease progression or recurrence
3 excessive toxicity
6 not in patient’s best interest
1 death  
2 other
300 started MAPIE treatment
298 assessable for toxicity (safety population)
211 completed MAPIE treatment
308 assigned to receive MAPIE (intention-to-treat population) 
8 did not receive MAPIE
5 treatment refusal‡
2 protocol violation
1 not in patient’s best interest
2 not assessed for toxicity
87 terminated treatment early
36 treatment refusal
21 disease progression or recurrence
16 excessive toxicity
7 not in patient’s best interest
1 lost to follow-up
1 death  
5 other
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Postoperative therapy is depicted in the appendix (p 10). 
Therapy consisted of MAP or MAPIE. Complete 
macroscopic resection of all disease for patients with initial 
metastases between weeks 11 and 20 was recommended. 
Imaging recommendations during treatment included a 
chest CT, a bone scan, and a plain radiograph of the 
primary tumour at 4-month intervals.
Cisplatin, doxorubicin, and methotrexate were 
administered at the same doses as given preoperatively. 
Ifosfamide (high dose 14 g/m²) at 2·8 g/m² per day with 
equidose mesna uroprotection was administered, 
followed by etoposide 100 mg/m² per day over 1 h on 
days 1–5 (three postoperative cycles). Two additional 
cycles of ifosfamide 3 g/m² per day with mesna 
uroprotection on days 1–3 (9 g/m²) were given, with 
standard doxorubicin. Investigators were allowed to use 
supportive care with myeloid growth factor support 
according to local practice. 
Patients treated with MAP received 29 weeks 
of treatment or four cycles of MAP and two cycles 
of methotrexate and doxorubicin (cisplatin was 
discontinued after a cumulative dose of 480 mg/m²). The 
protocol provided recommendations for dose reductions 
on the basis of the toxicity (from the common toxicity 
criteria) and therapy delays.
Outcomes 
The primary outcome measure was event-free survival, 
deﬁ ned as the time from randomisation until ﬁ rst 
event (local recurrence, evidence of new or progressive 
metastatic disease, second malignancy, death, or a 
combination of those events) or censoring at last contact. 
Data were provided to the Medical Research Council by 
each group, but the outcome was not centrally reviewed. 
Secondary outcomes were overall survival (deﬁ ned as the 
time from randomisation until death from any cause or 
last contact), short-term and long-term toxicity, and quality 
of life. Toxicity was measured by the treating institution 
and submitted to the Medical Research Council. Targeted 
toxicities included neutropenia, febrile neutropenia, fever 
without neutropenia, electrolyte abnormalities, cardiac 
dysfuction, renal dysfuction, and second malignancies. 
Serious adverse events were expedited (reported within 
1 business day). Quality of life was assessed using the 
European Organization for Research and Treatment of 
Cancer quality of life questionnaire (EORTC QLQ-30; for 
patients at least 16 years of age) and the Pediatric Quality 
of Life inventory (PedsQL; for patients younger than 
16 years of age). Questionaires were administered at 
baseline (before cycle 2), at week 20–22 (on active 
treatment), 18 months after start of treatment, and 3 years 
after starting treatment. Quality of life results will be 
published separately.
Statistical analysis
With international accrual, we sought to randomise 
693 patients with poor response to preoperative MAP. 
This and the partner trial in patients with a good 
response to preoperative MAP19,20 were thought to require 
registration before chemotherapy of around 1400 patients. 
MAP (n=310) MAPIE (n=308)
Sex
Male 174 (56%) 191 (62%)
Female 136 (44%) 117 (38%)
Age at registration (years)
<5 1 (<1%) 0
5–9 54 (17%) 40 (13%)
10–19 204 (66%) 231 (75%)
20–29 35 (11%) 32 (10%)
≥30 16 (5%) 5 (2%)
Median (IQR) 15 (11–17) 14 (12–17)
Range 4–40 5–39
Site of tumour
Femur 154 (50%) 166 (54%)
Tibia 75 (24%) 76 (25%)
Fibula 17 (5%) 13 (4%)
Humerus 39 (13%) 27 (9%)
Radius 4 (1%) 6 (2%)
Ulna 2 (1%) 1 (<1%)
Scapula/clavicle 3 (1%) 2 (1%)
Pelvis/sacrum 8 (3%) 11 (4%)
Rib 3 (1%) 3 (1%)
Other 5 (2%) 3 (1%)
Location of tumour on the bone
Proximal 114 (37%) 109 (35%)
Diaphysis 11 (4%) 12 (4%)
Distal 166 (54%) 168 (55%)
N/A (not long bone) 19 (6%) 19 (6%)
Pathological fracture at diagnosis
No 276 (89%) 270 (89%)
Yes 34 (11%) 35 (11%)
Data missing 0 3
Localised disease 265 (85%) 276 (90%)
Lung metastases
No* 272 (88%) 280 (91%)
Yes 38 (12%) 28 (9%)
Extra-pulmonary metastases
No* 302 (97%) 299 (97%)
Yes 8 (3%) 9 (3%)
Histological classiﬁ cation†
Conventional 288 (94%) 289 (95%)
Telangiectatic 11 (4%) 6 (2%)
Small cell 3 (1%) 2 (1%)
High-grade surface 5 (2%) 6 (2%)
Periosteal‡ 0 1 (<1%)
Biopsy data not available 3 4
MAP=methotrexate, doxorubicin, and cisplatin. MAPIE=MAP plus ifosfamide and etoposide. Missing values are not 
included in the percentage calculation. *Possible metastases were combined with no metastases. †Histological 
classiﬁ cation was based on diagnostic biopsy according to the WHO 2002 classiﬁ cation of osteosarcoma.27,28 
‡Patient with periosteal classiﬁ cation was considered eligible at registration. 
Table 1: Baseline characteristics
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This number was increased to more than 2000 registered 
patients overall, after the observed randomisation rate was 
lower than anticipated.19 The study required at least 
378 event-free survival events and at least 378 deaths to 
detect absolute improvements of 10% from 45% to 55% in 
3-year event-free survival and 5-year overall survival 
(hazard ratio [HR] 0·75) with 5% two-sided signiﬁ cance 
levels and 80% power.24 The estimated sample size was 
calculated with the George and Desu method, and 
although this number of events was not reached, the 
independent data monitoring committee recommended 
early release of data because of the lower than predicted 
event rate and low likelihood that the planned number 
of events would be reached in a reasonable time. 
A preplanned subgroup analysis for patients with localised 
disease required 270 events to detect an 11% improvement, 
from 50% to 61% (HR 0·71) in 3-year event-free survival, 
and 5-year survival (two-sided signiﬁ cance level 5%, power 
80%), assuming 85% of randomised patients would have 
localised disease (≥590 patients expected).
Primary and secondary outcomes were measured in 
the intention-to-treat population. Toxicity was assessed 
in the safety population which consisted of patients who 
started postoperative chemotherapy and who were 
assessed for toxicity. Statistical tests were done at a 
two-sided signiﬁ cance level of 0·05. The Kaplan-Meier 
method was used to estimate survival functions, 
log-rank test for diﬀ erences between survival curves and 
Cox models (adjusted for stratiﬁ cation factors) to 
estimate the treatment eﬀ ect. Median follow-up was 
calculated with reverse censoring on death. The χ² test 
was used in a prespeciﬁ ed analysis to compare the 
proportion of patients with grade 3 or worse toxicity 
between the treatment groups. Interim analyses 
were done at regular intervals and presented to 
the independent data monitoring committee. The 
Haybittle-Peto stopping rule was used, and the trial was 
planned to stop if the p value for the event-free survival 
analysis was less than 0·001. The interim analyses were 
designed to examine safety of the patients, and therefore 
the protocol prespeciﬁ ed that if at interim analysis, the 
lower bound of the 95% CI for the proportion of patients 
in each group who died because of toxicity exceeded 3%, 
the future of the trial would be discussed with the Trial 
Steering Committee.
The proportionality of hazards for the treatment 
eﬀ ect over time was tested. In the presence of 
non-proportionality, the diﬀ erence between the groups 
was estimated with restricted mean survival time 
(RMST)25,26 after ﬁ tting a ﬂ exible parametric model. 
RMST for event-free survival measures a mean 
time-to-ﬁ rst event, when time of consideration was 
restricted to t* years after randomisation; here t* was 
6 years. The consistency of treatment eﬀ ect in patients 
with localised or metastatic disease was tested by ﬁ tting 
a ﬂ exible parametric model with interaction between 
allocated treatment and metastases.
The treatment eﬀ ect was estimated separately in the 
prespeciﬁ ed localised disease subgroup, and in the 
following subgroups deﬁ ned post hoc: sex, age, site of 
disease, location of cancer on bone, and baseline 
metastases (lung and non-lung). Local recurrence, new 
Figure 2: Event-free survival 
(A) Kaplan-Meier curve of event-free survival. (B) Absolute diﬀ erence in event-free survival by ﬂ exible parametric 
model diﬀ erence. 95% CI is shown by shading. (C) Kaplan-Meier curve of event-free survival by metastases status 
at registration.  
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metastases, progression of existing metastases, death, or 
a combination of those events were considered a 
competing event for reporting second malignancy. 
Analyses were done with Stata version 14.0. This trial is 
registered with ClinicalTrials.gov, number NCT00134030. 
Role of the funding source
The funders of this study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. MRS and GJ had access to raw data. 
The corresponding author had full access to all data in 
the study and all authors had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between April 14, 2005, and June 30, 2011, 2260 patients 
were registered until the overall recruitment target was 
reached. The dataset was frozen on Nov 19, 2014. 
618 patients were randomly assigned from the poor 
responders group: 310 to receive MAP and 308 to receive 
MAPIE (ﬁ gure 1); this was lower than the anticipated 
target of 693. The main reasons for non-randomisation 
were no provision of consent (appendix p 4). Baseline 
characteristics at registration for the randomly assigned 
patients were similar between the groups (table 1). 
Median follow-up for the entire trial population 
was 62·1 months (IQR 46·6–76·6); 62·3 months 
(IQR 46·9–77·1) for the MAP group and 61·1 months 
(IQR 46·5–75·3) for the MAPIE group. For patients last 
reported alive and not lost to follow-up, 325 (87%) of 
373 had follow-up within 14 months before the data 
freeze. 29 (9%) of 310 patients in MAP and 23 (7%) of 
308 patients in MAPIE were permanently lost to 
follow-up more than 14 months before the data freeze.
307 event-free survival events were reported: 153 in the 
MAP group and 154 in the MAPIE group. The HR for 
event-free survival comparison in MAPIE versus MAP 
was 0·98 (95% CI 0·78–1·23, p=0·86), but the 
proportionality of hazards assumption did not hold 
(p=0·0003); therefore, we estimated event-free survival 
with the RMST approach. Mean time to ﬁ rst event was 
43·3 months (95% CI 40·1–46·4) for patients allocated 
to the MAP group, and 44·1 months (41·1–47·1) for 
patients allocated to the MAPIE group, over a period 
of 6 years from randomisation. The diﬀ erence in 
estimated RMST was 0·8 months (95% CI –3·3 to 4·9, 
p=0·69; ﬁ gure 2). The 3-year event-free survival 
estimates were 55% (95% CI 49–60) in the MAP group 
and 53% (47–59) in the MAPIE group (ﬁ gure 2). 
In both groups, the ﬁ rst event mostly involved 
metastases—133 (87%) of 153 patients in the MAP group 
and 129 (84%) of 154 patients in the MAPIE group.
247 event-free survival events were reported in 
541 patients with localised disease at the time of 
registration (118 in the MAP group and 129 in the MAPIE 
group; ﬁ gure 2). 3-year event-free survival estimates in 
localised disease were 60% (95% CI 54–66) in the MAP 
group and 57% (51–63) in the MAPIE group. The HR 
was 1·03 (0·81–1·33, p=0·80) but with considerable 
non-proportionality (p=0·0071). The diﬀ erence in 
estimated RMST between the MAPIE and MAP groups 
was 0·05 months (–4·7 to 4·8; p=0·98; ﬁ gure 2). 3-year 
event-free survival in patients who had metastases at 
registration was 24% (13–38) in the MAP group and 18% 
(6–33) in the MAPIE group. The event-free survival 
comparison in various subgroups is shown in the 
appendix (p 7). No evidence of heterogeneity of a 
treatment eﬀ ect across the explored subgroups was 
observed. 
193 deaths were reported (101 in the MAP group vs 
92 in the MAPIE group). Survival data are immature. 
With current data, the HR estimate was 0·97 
(95% CI 0·73–1·29, p=0·86) and at 3-years, overall 
survival was 72% (95% CI 67–77) for the MAP group and 
77% (72–81) for the MAPIE group (ﬁ gure 3). 
Details of received standardised postoperative 
chemotherapy doses, the number of patients who 
received the target number of chemotherapy doses, and 
the number of patients who received at least 80% of the 
planned dose are shown in table 2. Chemotherapy 
compliance was generally poorer with MAPIE than with 
MAP. Of the 77 patients with metastases at registration, 
75 of 77 either had resection or resection was no longer 
needed and two of 75 were not operated on (one in the 
MAPIE group due to clinician’s and patient’s choice 
group vs one in the MAP group who was inoperable).
Toxicity data are available for 301 (99·7%) of 302 MAP 
and 298 (99·3%) of 300 patients in the MAPIE group 
who started treatment (table 3), and the remaining 
three patients were not assessed for toxicity (one in 
the MAP group and two in the MAPIE group). 
Less commonly reported postoperative toxicities of 
grade 3 or 4, outside of those routinely solicited, are 
given in the appendix (p 8); information about raised 
liver enzymes, nausea, vomiting, and diarrhoea were not 
routinely collected, but were reported at the discretion of Figure 3: Kaplan-Meier curve of overall survival
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the site and are taken into consideration when highest 
grade toxicity reported was determined (table 4). The 
grades of the toxicities recorded during postoperative 
chemotherapy were similar between diﬀ erent treatment 
groups: worst toxicity of grade 3 or above was reported 
by 287 (95%) of 301 patients in MAP and 281 (94%) of 
298 in MAPIE group (table 4). MAPIE was associated 
with more frequent grade 4 non-haematological toxicity 
(35 [12%] of patients in the MAP group vs 71 [24%] of 
298 patients in the MAPIE group), mainly because of 
infections with absolute neutrophil count of less than 
1 × 10⁹ neutrophils per L, febrile neutropenia without 
documented infection, and hypophosphataemia (table 
4). Two patients died during postoperative therapy, one 
due to infection although they had a normal absolute 
neutrophil count (MAP group), and one due to left 
ventricular systolic dysfunction (MAPIE group). 
One suspected unexpected serious adverse reaction was 
reported in the MAP group: bone marrow infarction due 
to methotrexate. 19 patients discontinued because of 
drug-related toxicity; three in the MAP group and 16 in 
the MAPIE group. Dose was reduced or delayed 
according to criteria in the protocol for 176 (58%) of 
301 patients in the MAP group and 184 (62%) of 
298 patients in the MAPIE group. Three patients were 
not assessed for dose reduction or delay, one in the MAP 
group and two in the MAPIE group.
Left ventricular systolic dysfunction grade 3 events were 
reported in three (2%) of 134 patients in the MAPIE group 
and one (1%) of 136 in the MAP group. Long-term toxicity 
data was available from COSS, EOI, and SSG centres and 
reﬂ ects adverse events which might or might not be 
treatment related. Creatinine grade 3 events were reported 
for 3 (2%) out of 138 patients in the MAPIE group and no 
patients in MAP. Urinary electrolyte wasting grade 3 was 
reported for ﬁ ve (4%) of 134 patients in the MAPIE group 
and no patients in the MAP group. Renal failure grade 3 
(four [3%] of 138 patients) and grade 4 (one [1%] of 
138 patients) events were reported in the MAPIE group 
but not in the MAP group. There was no consistent 
pattern of reversibility for left ventricular systolic 
dysfunction or renal events, as some patients improved, 
whereas others did not, but the number of events was too 
small to analyse further.
13 second primary malignancies were reported (three in 
the MAP group vs ten in the MAPIE group; appendix 
pp 5, 6). Cause-speciﬁ c HR estimate for  MAPIE versus 
MAP was 3·24 (0·87–12·06), p=0·079; subdistribution 
HR was 3·21 (0·87–11·85), p=0·081; appendix p 6). Most 
of the second malignancies were myeloid (myelodysplasia 
and acute myeloid leukaemia): two of three in the MAP 
group and eight of ten in the MAPIE group, mostly 
recording cytogenetic abnormalities causally associated 
with administration of alkylating drugs (monosomy-7 or 
chromosome-5 abnormalities) or etoposide (11q23 
abnormalities). One of three patients in the MAP group 
and two of ten patients in the MAPIE group had second 
solid tumours. A longer follow-up will allow for more 
precise estimates.
Discussion
Standard treatment for high-grade osteosarcoma includes 
preoperative chemotherapy followed by surgical resection 
and postoperative chemotherapy.1–4,8 Although previous 
uncontrolled studies3,5,19 suggested that altering therapy 
on the basis of histological response improved outcome, 
this had not been tested in randomised controlled trials. 
EURAMOS-1 is, to the best of our knowledge, the ﬁ rst 
collaboration to assess in a randomised manner whether 
altering chemotherapy on the basis of histological 
response improves outcome for patients with osteo-
sarcoma. Our results for patients with a poor histological 
response show that the addition of ifosfamide and 
etoposide to standard postoperative therapy does not 
improve outcome and rather increases the incidence of 
toxic eﬀ ects. 
Target 
cumulative 
standardised 
dose
Median cumulative standardised 
dose (IQR)
Target 
number 
of doses
Patients (%) who received 
target number of doses
Received at least 80% of 
planned dose*
MAP MAPIE MAP (n=302) MAPIE 
(n=300)
MAP (n=302) MAPIE 
(n=299)† 
Methotrexate (g/m²) 96 93·9 (80·0–97·1) 87·9 (67·7–96·6) 8–10 226 (75%) 178 (59%) 235 (78%) 194 (65%)
Doxorubicin (mg/m²) 300 296 (284–303) 299 (233–305) 4 250 (83%) 233 (78%) 245 (81%) 221 (74%)
Cisplatin (mg/m²) 240 239 (235–241) 240 (230–244) 2 277 (92%) 251/299 
(84%)‡
267 (88%) 238/298 
(80%)‡
Ifosfamide 14 g (g/m²) 42 NA 40·8 (26·6–42·4) 3 NA 222 (74%) NA 204 (68%)
Ifosfamide 9 g (g/m²) 18 NA 17·4 (8·9–18·3) 2 NA 193 (64%) NA 190 (64%)
Etoposide (g/m²) 1·5 NA 1·47 (1·00–1·52) 3 NA 224 (75%) NA 211 (71%)
All patients received preoperative treatment. MAP=methotrexate, doxorubicin, and cisplatin. MAPIE=MAP plus ifosfamide and etoposide. NA=not applicable. *Percentages 
were calculated by dividing by the number of patients who received at least one dose of study drug. †Doses for MAPIE drugs are not known for  one patient who started 
MAPIE treatment; number of received cycles for each drug is known. ‡Received cisplatin dose and number of cycles are not known for one patient.
Table 2: Summary of patients who received postoperative MAP and MAPIE 
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MAP (n=301) MAPIE (n=298)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Any toxicity 11 (4%) 26 (9%) 260 (86%) 1 (<1%) 12 (4%) 20 (7%) 260 (87%) 1 (<1%)
Non-haematological event* 57 (19%) 197 (65%) 35 (12%) 1 (<1%) 24 (8%) 187 (63%) 71 (24%) 1 (<1%)
Infection in patients with absolute 
neutrophil count ≥1 × 10⁹ 
neutrophils per L 
35/209 (17%) 48/209
(23%) 
1/209 
(<1%)
1/209 
(<1%)
29/227 (13%) 57/227 (25%) 9/227 (4%) 0
Left ventricular systolic dysfunction 42/290 (14%) 2/290 (1%) 0 0 59/292 (20%) 3/292 (1%) 0 1/292 
(<1%)
Neutropenia 16 (5%) 21 (7%) 247 (82%) 0 11/295 (4%) 16/295 (5%) 252/295 
(85%)
0
Thrombocytopenia 44/298 (15%) 50/298 (17%) 181/298 (61%) 0 26/297 (9%) 36/297 (12%) 212/297 (71%) 0
Febrile neutropenia without 
documented infection 
0/299 138/299 
(46%)
11/299 (4%) 0 0 182/297 (61%) 35/297 (12%) 0
Anaemia † 19 (6%) 11 (4%) 0 † 17 (6%) 17 (6%) 0
Documented infection in patients 
with absolute neutrophil count 
<1 × 10⁹ neutrophils per L
19/300 (6%) 104/300 
(35%)
4/300 
(1%)
0 10/297 (3%) 135/297 (45%) 23/297 (8%) 0
Leucopenia † 2 (1%) 9 (3%) 0 † 2 (1%) 18 (6%) 0
Hypophosphataemia 70/286 (24%) 39/286 (14%) 4/286 (1%) 0 76/292 (26%) 59/292 (20%) 13/292 (4%) 0
Mucositis or stomatitis 118/267 (44%) 84/267 (31%) 6/267 (2%) 0 129/262 (49%) 70/262 (27%) 9/262 (3%) 0
Hypokalaemia † 1 (<1%) 0 0 † 3 (1%) 7 (2%) 0
Mood alteration 70/297 (24%) 2/297 (1%) 3/297 (1%) 0 74/297 (25%) 10/297 (3%) 3/297 (1%) 0
Hypomagnesaemia † 1 (<1%) 3 (1%) 0 † 0 1 (<1%) 0
Abnormal creatinine concentration 41/300 (14%) 2/300 (1%) 1/300 (<1%) 0 55/298 (18%) 5/298 (2%) 2/298 (1%) 0
Infection with unknown absolute 
neutrophil count
† 3 (1%) 1 (<1%) 0 † 4 (1%) 1 (<1%) 0 
Electrolyte abnormalities † 2 (1%) 1 (<1%) 0 † 4 (1%) 1 (<1%) 0
Infection with grade 3 or 4 
absolute neutrophil count 
† 3 (1%) 1 (<1%) 0 † 2 (1%) 1 (<1%) 0 
Thrombosis, thrombus, or embolism † 2 (1%) 1 (<1%) 0 † 1 (<1%) 1 (<1%) 0 
Pain † 10 (3%) 1 (<1%) 0 † 11 (4%) 0 0 
Abnormal bilirubin concentration‡ 53/147 (36%) 7/147 (5%) 0 0 63/147 (43%) 8/147 (5%) 1/147 (1%) 0
Encephalopathy † 3 (1%) 0 0 † 3 (1%) 1 (<1%) 0 
Hyperglycaemia † 3 (1%) 0 0 † 2 (1%) 1 (<1%) 0
Metabolic or other 
laboratory-conﬁ rmed event
† 2 (1%) 0 0 † 3 (1%) 1 (<1%) 0 
Seizure 4/300 (1%) 0 1/300 (<1%) 0 9/297 (3%) 1/297 (<1%) 0 0
Motor neuropathy 4/298 (1%) 12/298 (4%) 0 0 9/296 (3%) 11/296 (4%) 0 0
Hearing 60/270 (22%) 8/270 (3%) 0 0 74/274 (27%) 2/274 (1%) 0 0
Sensor neuropathy 39/299 (13%) 5/299 (2%) 0 0 31/297 (10%) 5/297 (2%) 0 0
Somnolence 2/300 (1%) 1/300 (<1%) 0 0 17/295 (6%) 6/295 (2%) 0 0
Confusion 5/298 (2%) 0 0 0 19/296 (6%) 6/296 (2%) 0 0
Typhlitis 6/298 (2%) 2/298 (1%) 0 0 8/292 (3%) 4/292 (1%) 0 0
Allergic reaction † 2 (1%) 0 0 † 4 (1%) 0 0
Urinary electrolyte wasting 20/275 (7%) 0 0 0 22/266 (8%) 4/266 (2%) 0 0
Glomerular ﬁ ltration rate 22/255 (9%) 0 0 0 36/263 (14%) 1/263 (<1%) 0 0
Haemorrhage, genitourinary bladder 13/297 (4%) 0 0 0 22/294 (7%) 1/294 (<1%) 0 0
All grade 3–5 adverse events are shown for all routinely collected toxicities; additionally, any toxicity of a type that was not routinely solicited on the case report forms, but 
was reported for at least ﬁ ve patients is included. Grade 1–2 adverse events are also included if reported for at least 10% of patients. Percentages for each toxicity were 
determined by dividing by the total number of patients who had information about that particular toxicity. Three patients (one receiving MAP and two receiving MAPIE) 
were not assessed for toxicity and are not included in the table above. MAP=methotrexate, doxorubicin, and cisplatin. MAPIE=MAP plus ifosfamide and etoposide. 
*Any toxicity, excluding neutropenia, thrombocytopenia, anaemia, and leucopenia. †Toxicities not routinely solicited; sites could only report these under “other” toxicities. 
‡Bilirubin data was collected by the Cooperative Osteosarcoma Study Group, the European Osteosarcoma Intergroup, and the Scandinavian Sarcoma Group sites only.
Table 3: Postoperative treatment-related adverse events 
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A previous randomised controlled trial29 of around 
240 patients assessed the addition of ifosfamide to 
standard MAP chemotherapy for patients with 
osteosarcoma. This trial included an upfront random-
isation to MAP versus MAP plus ifosfamide, with 
postoperative ifosfamide given to those who had received 
it preoperatively or whose tumour showed a poor 
histological response to preoperative MAP (<90% 
necrosis). No signiﬁ cant diﬀ erence in outcome was 
observed between the two groups and the timing of the 
addition of ifosfamide made no diﬀ erence to outcome. 
On the basis of these data and our EURAMOS results, 
we recommend continuing with the same chemotherapy 
as used preoperatively for patients with a poor histological 
response to preoperative treatment. 
Our results are also consistent with the results of a 
previous randomised controlled trial2 by the COG, which 
COG assessed the role of ifosfamide and mifamurtide in 
patients with osteosarcoma. The study assessed whether 
the addition of ifosfamide or mifamurtide to the MAP 
regimen improved long-term outcomes; patients were 
treated preoperatively with either MAP or MAP plus 
ifosfamide, and subsequently postoperatively treated with 
or without mifamurtide. No diﬀ erence in histological 
response was observed after the preoperative period, and 
no diﬀ erence in event-free survival or overall survival was 
observed between the two chemotherapy groups. Our 
results are also consistent with the conclusion of a 
meta-analysis30 where outcomes for osteosarcoma patients 
were improved with the use of at least three drugs, but no 
improvement was noted with the use of MAP plus 
ifosfamide versus MAP.
EURAMOS-1 was complicated by a lower than 
anticipated randomisation rate, probably related to the 
timing of the randomisation, close to the time of the 
intervention, after patients had been exposed to signiﬁ cant 
treatment-related toxicities. Non-randomisation was 42% 
in known poor responders and occurred in all four trial 
groups (COG, COSS, EOI, and SSG) ranging between 
33% and 45%. Disease progression during preoperative 
treatment was reported in some patients, who were 
ineligible for randomisation. Four patients were 
considered ineligible at retrospective central pathology 
review. These patients were included because the treating 
clinician thought them eligible. This highlights the 
diagnostic diﬃ  culties facing physicians, pathologists, 
and patients. 
As anticipated, a larger number of MAPIE-treated 
patients developed second malignancies than patients 
treated with MAP, although the diﬀ erence was not 
statistically signiﬁ cant. Most of these second 
malignancies were myeloid in origin, which is not 
unexpected given the short follow-up and the natural 
history of therapy-related myeloid disorders.31,32 The 
cytogenetic abnormalities in some of these leukaemias 
were consistent with exposure to alkylating drugs32 and 
etoposide.33 Although second solid malignancies are 
more common after combined modality therapy, 
including irradiation,34 alkylating drugs also contribute to 
this risk. Therefore, continued follow-up is crucial to 
identify any second solid malignancies occurring as later 
events in this patient population. Overall survival will 
additionally be analysed with longer follow-up.
The number of events was lower than anticipated, 
as event-free survival results were based on 307 event-free 
survival events, rather than the planned 378; event 
rate was lower than predicted and our 3-year event-free 
survival estimate for MAP was 55% (95% CI 49–60) 
rather than 45%. Follow-up visits started later in the 
MAPIE group because treatment was longer (40 weeks vs 
29 weeks). Therefore early imaging assessments might 
not have been identically timed by group, resulting in the 
apparent early separation observed in the event-free 
survival curve in favour of the MAPIE group. 
The timing of our intervention might have been too 
late because the ﬁ rst cycle of ifosfamide plus etoposide 
was administered at week 17 (5 weeks from resumption 
of postoperative therapy). Also, the overall intensity of 
therapy might have contributed to the inability of 
MAPIE-treated patients to receive all intended treatment. 
Ultimately, the best strategy for patients with a poor 
histological response might not be therapy intensiﬁ cation 
since this approach has been unsuccessful in childhood 
soft tissue sarcomas35 and in a previous study in 
osteosarcoma.4 The use of functional imaging early 
during treatment might identify patients who will have a 
poor response and allow incorporation of alternative 
treatment strategies earlier. This technique has been 
assessed in patients with osteosarcoma36 and found to 
predict both histological response and outcome. 
We included patients with both initially localised and 
initially metastatic disease in the same trial because it 
was not always possible to diﬀ erentiate up-front 
between patients with localised disease and those with 
MAP (n=301) MAPIE (n=298) χ² test p value*
Grade 3 Grade 4 Grade 5 Total grade 3 or worse Grade 3 Grade 4 Grade 5 Total grade 3 or worse
Any toxicity 26 (9%) 260 (86%) 1 (<1%) 287 (95%) 20 (7%) 260 (87%) 1 (<1%) 281 (94%) p=0·56
Non-haematological events† 197 (65%) 35 (12%) 1 (<1%) 233 (77%) 187 (63%) 71 (24%) 1 (<1%) 259 (87%) p=0·0024
*Comparison of grade 3 or higher toxicity. †Any toxicity, excluding neutropenia, thrombocytopenia, anaemia, and leucopenia.
Table 4: Summary of worst grade toxicity during postoperative chemotherapy
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metastatic disease, and we have therefore also included 
patients with “possible” metastatic disease; other 
prognostic factors are the same in patients with both 
metastatic and localised disease. The inclusion of 
patients with initial metastases into the EURAMOS-1 
trial was unique. The patients with localised disease 
needed to have no metastatic progression during 
preoperative therapy to be eligible for randomisation. 
Additionally, these patients had to undergo resection of 
all metastatic lesions during the postoperative period. 
The 3-year event-free survival for patients with 
metastases was 24% (13–38) in the MAP group and 18% 
(6–33) in the MAPIE group, and these results are 
similar to those of other published series.37,38 The 
EURAMOS-1 trial included only 77 patients with 
metastases, which makes it diﬃ  cult to draw ﬁ rm 
conclusions regarding the outcome for these patients. 
Additionally, since the EURAMOS-1 patients with 
metastases needed to have resectable disease, the 
population included might not be entirely comparable 
to those included in the previous trials. 
Our trial has several strengths, including being an 
international randomised controlled trial in a rare disease 
with widely applicable results. It also has several 
limitations including the lower-than-expected acceptance 
of randomisation and the lower-than-predicted observed 
event rate. The percentage of viable tumours22,23 at the 
individual patient level was not collected in this study. 
This limits our ability to assess overall prognosis by 
percentage of viable tumour. Because the study question 
was whether altering therapy on the basis of histological 
response improved outcome, we do not think collection of 
those data is crucial to the study results overall. Another 
potential limitation is the fact that we did not include 
central imaging review. This could have resulted in local 
sites removing patients from the study for apparent local 
disease progression, which might actually have had 
represented only pseudoprogression. In addition, the 
inclusion of patients deemed to have resectable metastases 
without undergoing central review increases the 
possibility that those patients did not truly have resectable 
disease. The fact that a higher proportion of patients with 
metastatic disease were not randomised raises the 
possibility that some local institutions misjudged the 
ability to do a complete resection. The number of patients 
removed from protocol therapy because metastases were 
unresectable might be anticipated to be balanced between 
the treatment groups. Lastly, although we collected total 
dose received by each patient, we did not collect it in a way 
that allows us to present relative dose intensity received. 
This is a potential limitation especially because patients 
treated in the experimental group appeared to receive less 
of the intended therapy.
The addition of mifamurtide to the MAP chemotherapy 
regimen for patients with localised osteosarcoma resulted 
in improved overall survival.2 The drug was approved for 
use in Europe on the basis of those results, but has not 
been approved for use in the USA. However, the results 
suggest that assessment of drugs such as mifamurtide 
that stimulate the immune system might improve 
outcome. We have subsequently reached an apparent 
plateau in outcomes for patients with osteosarcoma.39 The 
development of strategies to better understand the biology 
of this tumour40 might aid in the identiﬁ cation of drug 
targets. Collaboration with veterinary oncologists might 
speed up target identiﬁ cation in human beings as 
canine osteosarcoma is more common than human 
osteosarcoma.41 Genome-wide analysis of osteosarcoma 
samples might also help identify important targetable 
genetic mutations.42 The identiﬁ cation of genetic 
alterations that could be used as therapeutic targets is an 
important step to develop better treatment approaches.
Overall, EURAMOS-1 showed that treatment with 
MAPIE resulted in similar event-free survival to MAP, 
results in increased toxicity, decrease in total received 
doses, and more second malignancies. Therefore, we 
argue strongly against adding ifosfamide and etoposide 
to the backbone of MAP therapy for patients whose 
tumour shows a poor response to preoperative treatment. 
Future strategies might seek to incorporate drugs 
with diﬀ erent mechanisms of action either alongside 
postoperative chemotherapy or earlier in the treatment 
pathway of appropriately identiﬁ ed patients. Such trials 
will require continued international collaboration by the 
EURAMOS group.
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